ScripRoche is upping its game for the blockbuster ophthalmic drug Vabysmo (faricimab) in a bid to seize more market share from established contenders in Asia, especially China, where the novel therapy is a
Scrip10 years ago, business talks involving Chinese pharma firms mostly focused on trying to get some attention from established biopharma giants and venture capital investors. The tone today is more on be
Pink SheetAmong the many words used to describe the current Chinese pharma market, from “hot” to “crowded” to "booming", the most common is “exciting.” After all, China’s health sector has quickly emerged from
ScripYangtze River Pharma has become the first pharma firm to receive a hefty fine amid a new wave of antitrust crackdowns in China that started with big tech companies but is now quickly expanding to othe